nach oben

Erschienen in:

01.08.2013 | Guideline

Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version

JSN, JRS, and JCS Joint Working Group

verfasst von: Iwao Ohno, Hiromitsu Hayashi, Kazutaka Aonuma, Masaru Horio, Naoki Kashihara, Hirokazu Okada, Yasuhiro Komatsu, Shozo Tamura, Kazuo Awai, Yasuyuki Yamashita, Ryohei Kuwatsuru, Atsushi Hirayama, Yoshihiko Saito, Toyoaki Murohara, Nagara Tamaki, Akira Sato, Tadateru Takayama, Enyu Imai, Yoshinari Yasuda, Daisuke Koya, Yoshiharu Tsubakihara, Shigeo Horie, Yukunori Korogi, Yoshifumi Narumi, Katsumi Hayakawa, Hiroyuki Daida, Koichi Node, Isao Kubota

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

Diagnostic imaging using iodinated contrast media is an essential procedure in the clinical setting, and provides a large amount of beneficial information. However, the use of iodinated contrast media may cause contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD), and guidelines on the use of contrast media in this patient population have long been awaited. Although international societies such as the European Society of Urogenital Radiology (ESUR) and the American College of Radiology (ACR) have published guidelines on this matter, no guidelines have been proposed in Japan. Therefore, the Japan Radiological Society (JRS), the Japanese Circulation Society (JCS), and the Japanese Society of Nephrology (JSN) decided to collaborate to establish guidelines on the use of iodinated contrast media in patients with kidney disease. …

Nur mit Berechtigung zugänglich

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;2013(3):19–62.

Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, CIN Consensus Working Panel, et al. Baseline renal function screening. Am J Cardiol. 2006;98:21K–6K [VI].PubMedCrossRef

Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–9 [IVb].PubMedCrossRef

Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–64 [IVb].PubMedCrossRef

Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol. 2008;3:1274–81 [IVa].PubMedCrossRef

Kim SM, Cha RH, Lee JP, Kim DK, Oh KH, Joo KW, et al. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am J Kidney Dis. 2010;55:1018–25 [IVb].PubMedCrossRef

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR), et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527–41 [VI].PubMedCrossRef

McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419–28 [I].PubMedCrossRef

Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254–61 [II].PubMedCrossRef

10.

Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320:143–9 [III].PubMedCrossRef

11.

McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692–9 [I].PubMedCrossRef

12.

Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine. Ann Acad Med Singapore. 2010;39:374–80 [IVa].PubMed

13.

La Manna G, Pancaldi LG, Capecchi A, Maska E, Comai G, Cappuccilli ML, et al. Risk for contrast nephropathy in patients undergoing coronarography. Artif Organs. 2010;34:E193–9 [IVb].PubMedCrossRef

14.

Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of renin–angiotensin–aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant. 2010;25:759–64 [IVb].PubMedCrossRef

15.

Saudan P, Muller H, Feraille E, Martin PY, Mach F. Renin–angiotensin system blockade and contrast-induced renal toxicity. J Nephrol. 2008;21:681–5 [IVa].PubMed

16.

Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008;40:749–55 [IVa].PubMedCrossRef

17.

Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69:135–40.PubMedCrossRef

18.

Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taqylor DA, Teo KK. Forced euvolemic diuretic with mannitol and furosecemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54:602–9 [I].PubMedCrossRef

19.

Solomon R, Wener C, Mann D, D’Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decrease in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416–20 [II].PubMedCrossRef

20.

Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, REMEDIAL II Investigators, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124:1260–9 [II].PubMedCrossRef

21.

Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5:90–7 [II].PubMedCrossRef

22.

Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case–control analysis. Am J Epidemiol. 2006;164:881–9 [IVb].PubMedCrossRef

23.

Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–86 [V].PubMedCrossRef

24.

Jain V, Sharma D, Prabhakar H, Dash HH. Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity. Eur J Anaesthesiol. 2008;25:166–7 [V].PubMedCrossRef

25.

Safadi R, Dranitzki-Elhalel M, Popovtzer M, Ben-Yehuda A. Metformin-induced lactic acidosis associated with acute renal failure. Am J Nephrol. 1996;16:520–2 [V].PubMedCrossRef

26.

Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255:179–87 [V].PubMedCrossRef

27.

McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media—a dangerous combination? Clin Radiol. 1999;54:29–33 [I].PubMedCrossRef

28.

Rasuli P, Hammond DI. Metformin and contrast media: where is the conflict? Can Assoc Radiol J. 1998;49:161–6 [VI].PubMed

29.

Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254:261–9 [I].PubMedCrossRef

30.

Khurana R, Malik IS. Metformin: safety in cardiac patients. Heart. 2010;96:99–102 [VI].PubMed

31.

Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? Diabetologia. 2005;48:2454–9 [VI].PubMedCrossRef

32.

Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol. 2009;29:136–44 [IVa].PubMedCrossRef

33.

From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc. 2008;83:1095–100 [IVa].PubMedCrossRef

34.

Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–8 [IVa].PubMedCrossRef

35.

Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105:624–8 [IVa].PubMedCrossRef

36.

Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769–75 [IVa].PubMedCrossRef

37.

Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780–5 [IVa].PubMedCrossRef

38.

McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–75 [IVa].PubMedCrossRef

39.

Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170–7 [IVa].PubMedCrossRef

40.

Heitmeyer C, Hölscher B, Fobker M, Breithardt G, Hausberg M, Reinecke H. Prognostic value of different laboratory measures of renal function for long-term mortality after contrast media-associated renal impairment. Clin Cardiol. 2010;33:E51–9 [IVa].PubMedCrossRef

41.

Jujo K, Yamaguchi J, Obayashi K, Suzuki K, Sekiguchi H, Nagashima M, et al. Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial Infarction undergoing emergent coronary angiography. J Cardiol. 2006;48:9–16 (in Japanese) [IVa].PubMed

42.

Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256:21–8 [IVa].PubMedCrossRef

43.

Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008;3:1242–3 [VI].PubMedCrossRef

44.

Matsushima K, Peng M, Schaefer EW, Pruitt JH, Kashuk JL, Frankel HL. Posttraumatic contrast-induced acute kidney injury: minimal consequences or significant threat? J Trauma. 2011;70:415–9 [IVa].PubMedCrossRef

45.

Rashid AH, Brieva JL, Stokes B. Incidence of contrast-induced nephropathy in intensive care patients undergoing computerised tomography and prevalence of risk factors. Anaesth Intensive Care. 2009;37:968–75 [IVa].PubMed

46.

Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant. 2006;21:1040–5 [IVa].PubMedCrossRef

47.

Dittrich E, Puttinger H, Schillinger M, Lang I, Stefenelli T, Hörl WH, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients—a prospective study. Nephrol Dial Transplant. 2006;21:1334–9 [IVa].PubMedCrossRef

48.

Brown JR, DeVries JT, Piper WD, Robb JF, Hearne MJ, Ver Lee PM, Northern New England Cardiovascular Disease Study Group, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J. 2008;155:260–6 [IVa].PubMedCrossRef

49.

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–9 [II].PubMed

50.

Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:S11–5 [VI].PubMedCrossRef

51.

Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649–52 [IVb].PubMedCrossRef

52.

Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49:658–67 [V].PubMedCrossRef

53.

Brown JR, Robb JF, Block CA, Schoolwerth AC, Kaplan AV, O’Connor GT, et al. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv. 2010;3:346–50 [II].PubMedCrossRef

54.

Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171–8 [I].PubMed

55.

Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–9 [II].PubMedCrossRef

56.

Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Investigators of the CARE Study, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189–96 [II].PubMedCrossRef

57.

Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250:68–86 [I].PubMedCrossRef

58.

Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int. 2006;70:1811–7 [IVb].PubMedCrossRef

59.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, et al. Focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;2009(120):2271–306.CrossRef

60.

Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:2022–60.PubMedCrossRef

61.

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651.PubMedCrossRef

62.

Chou SH, Wang ZJ, Kuo J, Cabarrus M, Fu Y, Aslam R, et al. Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration. Eur J Radiol. 2011;80:378–86 [IVb].PubMedCrossRef

63.

Lufft V, Lufft LH, Fels LM, Baiyee DE, Tusch G, Galanski M, et al. Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis. 2002;40:236–42 [II].PubMedCrossRef

64.

Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol. 2000;54:11–4 [IVb].PubMed

65.

Tepel M, van der Geit M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–4 [II].PubMedCrossRef

66.

Becker CR, Reiser MF. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol. 2005;40:672–5 [IVa].PubMedCrossRef

67.

Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computer tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41:815–21 [II].PubMedCrossRef

68.

Thomsen HS, Morcos SK, Earley CM, Grazioli L, Bonomo L, Ni Z, Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study, et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170–8 [II].PubMedCrossRef

69.

Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. Am J Roentgenol. 2008;191:151–7 [II].CrossRef

70.

Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248:97–105 [II].PubMedCrossRef

71.

Gallotti A, Uggeri F, Favilla A, Cabrini M, de Haën C. The chemistry of iomeprol and physico-chemical properties of its aqueous solutions and pharmaceutical formulations. Eur J Radiol. 1994;18(Suppl 1):S1–12 [VI].PubMedCrossRef

72.

Sovak M. The need for improved contrast media. Ioxilan: updating design theory. Invest Radiol. 1988;23(Suppl 1):S79–83 [VI].PubMedCrossRef

73.

Shiraki K, Otani H, Ohno Z, Takeuchi R, Hirai M, Murata K, et al. Case study of contrast-induced nephropathy using cardiac catheterization. Jpn Circ J. 2001;65(Suppl III):750 (in Japanese) [IVb].

74.

Fujisaki K, Nakayama M, Yoshimitsu T, Doi T, Tanaka R, Yamada A, et al. Incidence of contrast-induced nephropathy using cardiac catheterization: a case report. Jpn J Nephrol. 2002;44:315 (in Japanese) [IVb].

75.

Abe M, Kimura T, Morimoto T, Furukawa Y, Kita T. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J. 2009;73:1518–22 [IVb].PubMedCrossRef

76.

Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, NHLBI Dynamic Registry Investigators, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584–90 [IVb].PubMedCrossRef

77.

Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58:907–14 [IVb].PubMedCrossRef

78.

Chong E, Poh KK, Liang S, Soon CY, Tan HC. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol. 2010;23:451–9 [IVa].PubMedCrossRef

79.

Machino-Ohtsuka T, Seo Y, Ishizu T, Sekiguchi Y, Sato A, Tada H, et al. Combined assessment of carotid vulnerable plaque, renal insufficiency, eosinophilia, and hs-CRP for predicting risky aortic plaque of cholesterol crystal embolism. Circ J. 2010;74:51–8 [IVb].PubMedCrossRef

80.

Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A, Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003;42:211–6 [IVb].PubMedCrossRef

81.

Funabiki K, Masuoka H, Shimizu H, Emi Y, Mori T, Ito M, et al. Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature. Jpn Heart J. 2003;44:767–74 [IVb].PubMedCrossRef

82.

Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12:1781–7 [IVb].PubMed

83.

Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36:1089–109 [IVb].PubMed

84.

Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840–50 [IVb].PubMedCrossRef

85.

Thadhani RI, Camargo CA Jr, Xavier RJ, Fang LS, Bazari H. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore). 1995;74:350–8 [IVb].CrossRef

86.

Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38:769–84 [IVb].PubMedCrossRef

87.

Oleinik A, Romero JM, Schwab K, Lev MH, Jhawar N, Delgado Almandoz JE, et al. CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy. Stroke. 2009;40:2393–7 [IVa].PubMedCrossRef

88.

Herts BR, Schneider E, Obuchowski N, Poggio E, Jain A, Baker ME. Probability of reduced renal function after contrast-enhanced CT: a model based on serum creatinine level, patient age, and estimated glomerular filtration rate. AJR Am J Roentgenol. 2009;193:494–500 [IVb].PubMedCrossRef

89.

Hipp A, Desai S, Lopez C, Sinert R. The incidence of contrast-induced nephropathy in trauma patients. Eur J Emerg Med. 2008;15:134–9 [IVa].PubMedCrossRef

90.

Lencioni R, Fattori R, Morana G, Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT)—a clinical problem in daily practice? A multicenter observational study. Acta Radiol. 2010;51:741–50 [IVa].PubMedCrossRef

91.

Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Isr Med Assoc J. 2009;11:460–4 [IVb].PubMed

92.

Cramer BC, Parfrey PS, Hutchinson TA, Baran D, Melanson DM, Ethier RE, et al. Renal function following infusion of radiologic contrast material. A prospective controlled study. Arch Intern Med. 1985;145:87–9 [IVa].PubMedCrossRef

93.

Langner S, Stumpe S, Kirsch M, Petrik M. No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium. AJNR Am J Neuroradiol. 2008;29:1525–9 [IVa].PubMedCrossRef

94.

Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner G. Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in mL/min. Acta Radiol. 2005;46:830–42 [I].PubMedCrossRef

95.

Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol. 2008;51:89–90 [V].PubMedCrossRef

96.

Abujudeh HH, Gee MS, Kaewiai R. In emergency situations, should serum creatinine be checked in all patients before performing second contrast CT examinations within 24 hours? J Am Coll Radiol. 2009;6:268–73 [V].PubMedCrossRef

97.

Trivedi H, Foley WD. Contrast-induced nephropathy after a second contrast exposure. Ren Fail. 2010;32:796–801 [V].PubMedCrossRef

98.

Hopyan JJ, Gladstone DJ, Mallia G, Schiff J, Fox AJ, Symons SP, et al. Renal safety of CT angiography and perfusion imaging in the emergency evaluation of acute stroke. AJNR Am J Neuroradiol. 2008;29:1826–30 [V].PubMedCrossRef

99.

Lima FO, Lev MH, Levy RA, Silva GS, Ebril M, de Camargo EC, et al. Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy. AJNR Am J Neuroradiol. 2010;31:817–21 [IVa].PubMedCrossRef

100.

Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010;5:4–9 [V].PubMedCrossRef

101.

Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography. Am J Med. 1980;68:43–6 [V].PubMedCrossRef

102.

Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol. 1981;136:859–61 [V].PubMedCrossRef

103.

Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29–34 [II].PubMedCrossRef

104.

Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007;49:1283–8 [II].PubMedCrossRef

105.

Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329–36 [II].PubMedCrossRef

106.

Wróbel W, Sinkiewicz W, Gordon M, Woźniak-Wiśniewska A. Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions. Kardiol Pol. 2010;68:1015–20 [II].PubMed

107.

Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114:1570–4 [II].PubMedCrossRef

108.

Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120–6 [II].PubMedCrossRef

109.

Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009;151:631–8 [I].PubMedCrossRef

110.

Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23 [I].PubMedCrossRef

111.

Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol. 2009;41:617–27 [I].PubMedCrossRef

112.

Hogan SE, L’Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156:414–21 [I].PubMedCrossRef

113.

Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120:742–8 [I].PubMedCrossRef

114.

Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:617–27 [I].PubMedCrossRef

115.

Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2010;74:288–96 [I].PubMed

116.

Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300:1038–46 [II].PubMedCrossRef

117.

Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1584–92 [I].PubMedCrossRef

118.

Ueda H, Yamada T, Masuda M, Okuyama Y, Morita T, Furukawa Y, et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol. 2011;107:1163–7 [II].PubMedCrossRef

119.

Tamura A, Goto Y, Miyamoto K, Naono S, Kawano Y, Kotoku M, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol. 2009;104:921–5 [II].PubMedCrossRef

120.

Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol. 2011;107:1604–8 [II].PubMedCrossRef

121.

Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011;107:1447–52 [II].PubMedCrossRef

122.

Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54:610–8 [II].PubMedCrossRef

123.

Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol. 2010;23:216–23 [II].PubMed

124.

Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009;22:556–63 [II].PubMedCrossRef

125.

Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699–702 [II].PubMed

126.

Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1–7 [II].PubMed

127.

Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599–604.PubMedCrossRef

128.

DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol. 1997;272:F292–8 [VI].PubMed

129.

Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422–9 [II].PubMedCrossRef

130.

Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005;17:80–4 [II].PubMed

131.

Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–82 [II].PubMedCrossRef

132.

Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250–9 [II].CrossRef

133.

Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–94 [I].PubMedCrossRef

134.

Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(874):e9–15 [I].PubMed

135.

Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140–5 [I].PubMedCrossRef

136.

Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366–74 [I].PubMedCrossRef

137.

Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761–9 [I].PubMedCrossRef

138.

Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32 [I].PubMedCrossRef

139.

Anderson SM, Park ZH, Patel RV. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy. Ann Pharmacother. 2011;45:101–7 [I].PubMedCrossRef

140.

Trivedi H. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Ann Intern Med. 2008;149:213 (author reply 215–216 [VI]).

141.

Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–10 [VI].PubMedCrossRef

142.

Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007;189:687–92 [VI].PubMedCrossRef

143.

Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84:170–9 [VI].PubMedCrossRef

144.

Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol. 1991;261:F1102–9 [VI].PubMed

145.

Meyer-Lehnert H, Bayer T, Predel HG, Glanzer K, Kramer HJ. Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure. Klin Wochenschr. 1991;69:895–903 [VI].PubMedCrossRef

146.

Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Intensive Care Med. 1996;22:230–6 [IVa].PubMedCrossRef

147.

Kurnik BR, Weisberg LS, Cuttler IM, Kurnik PB. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med. 1990;116:27–36 [II].PubMed

148.

Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259–65 [II].PubMedCrossRef

149.

Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674–80 [II].PubMedCrossRef

150.

Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53:1040–6 [II].PubMedCrossRef

151.

Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiol. 2010;6:641–8 [II].CrossRef

152.

Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–42 [II].PubMedCrossRef

153.

Naidu KA. Vitamin C in human health and disease is still a mystery? An overview. Nutr J. 2003;2:7–16 [II].PubMedCrossRef

154.

Briguori C, Airoldi F, D’Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211–7 [II].PubMed

155.

Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2006;82:1381–90 [VI].CrossRef

156.

Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843–9 [IVa].PubMedCrossRef

157.

Patti G, Nusca A, Chello M, Pasceri V, D’Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279–85 [IVa].PubMedCrossRef

158.

Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011;33:344–51 [I].PubMedCrossRef

159.

Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol. 2011;153:323–5 [I].PubMedCrossRef

160.

Vogt B, Ferrari P, Schönholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001;111:692–8 [I].PubMedCrossRef

161.

Sterner G, Frennby B, Kurkus J, Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol. 2000;34:323–6 [I].PubMedCrossRef

162.

Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant. 1998;13:358–62 [I].PubMedCrossRef

163.

Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003;60:176–82 [I].PubMed

164.

Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol. 2007;96:130–9 [I].PubMedCrossRef

165.

Shiragami K, Fujii Z, Sakumura T, Shibuya M, Takahashi N, Yano M, et al. Effect of a contrast agent on long-term renal function and the efficacy of prophylactic hemodiafiltration. Circ J. 2008;72:427–33 [I].PubMedCrossRef

166.

Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007;50:1015–20 [I].PubMedCrossRef

167.

Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333–40 [I].PubMedCrossRef

168.

Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119:155–62 [I].PubMedCrossRef

169.

Song K, Jiang S, Shi Y, Shen H, Shi X, Jing D. Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Nephrol. 2010;32:497–504 [II].PubMedCrossRef

170.

Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweiz Med Wochenschr. 1996;126:666–73 [II].PubMed

171.

Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant. 1997;12:2592–6 [II].PubMedCrossRef

172.

Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–53 [IVa].PubMedCrossRef

173.

Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL, High-Dose Furosemide in Acute Renal Failure Study Group. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004;44:402–9 [II].PubMed

174.

Uchino S, Doig GS, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Diuretics and mortality in acute renal failure. Crit Care Med. 2004;32:1669–77 [IVa].PubMedCrossRef

175.

Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006;333:420 [I].PubMedCrossRef

176.

Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc. 2007;9:60–8 [I].PubMed

177.

Payen D, de Pont AC, Sakr Y, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74 [IVb].PubMedCrossRef

178.

Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–7 [IVa].PubMedCrossRef

179.

Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260–3 [II].PubMedCrossRef

180.

Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000;356:2139–43 [II].PubMedCrossRef

181.

Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526–31 [I].PubMedCrossRef

182.

Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510–24 [I].PubMedCrossRef

183.

Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med. 2002;28:877–83 [I].PubMedCrossRef

184.

Ichai C, Passeron C, Carles M, Bouregba M, Grimaud D. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in haemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med. 2000;28:1329–35 [II].PubMedCrossRef

185.

Lauschke A, Teichgraber UK, Frei U, Eckardt KU. Low-dose dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006;69:1669–74 [II].PubMedCrossRef

186.

Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, et al. Anaritide in acute tubular necrosis. N Engl J Med. 1997;336:828–34 [II].PubMedCrossRef

187.

Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, et al. Atrial natriuretic factor in oliguric acute renal failure. Am J Kidney Dis. 2000;36:767–74 [II].PubMedCrossRef

188.

Swaerd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med. 2004;32:1310–5 [II].CrossRef

189.

Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:261–72 [I].PubMedCrossRef

190.

Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002;30:2205–11 [II].PubMedCrossRef

191.

Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915–9 [IVa].PubMedCrossRef

192.

Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jabber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008;52:272–84 [I].PubMedCrossRef

193.

Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TW. Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int. 2010;14:11–7 [IVa].PubMedCrossRef

194.

Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care. 2009;24:129–40 [IVa].PubMedCrossRef

195.

Shiao CC, Wu VC, Li WY, Lin YF, Hu FC, Young GH, National Taiwan University Surgical Intensive Care Unit-Associated Renal Failure Study Group, et al. Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. Crit Care. 2009;13:R171 [IVa].PubMedCrossRef

196.

Iyem H, Tavli M, Akcicek F, Bueket S. Importance of early dialysis for acute renal failure after an open-heart surgery. Hemodial Int. 2009;13:55–61 [IVa].PubMedCrossRef

Titel: Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version
JSN, JRS, and JCS Joint Working Group
verfasst von: Iwao Ohno
Hiromitsu Hayashi
Kazutaka Aonuma
Masaru Horio
Naoki Kashihara
Hirokazu Okada
Yasuhiro Komatsu
Shozo Tamura
Kazuo Awai
Yasuyuki Yamashita
Ryohei Kuwatsuru
Atsushi Hirayama
Yoshihiko Saito
Toyoaki Murohara
Nagara Tamaki
Akira Sato
Tadateru Takayama
Enyu Imai
Yoshinari Yasuda
Daisuke Koya
Yoshiharu Tsubakihara
Shigeo Horie
Yukunori Korogi
Yoshifumi Narumi
Katsumi Hayakawa
Hiroyuki Daida
Koichi Node
Isao Kubota
Publikationsdatum: 01.08.2013
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 4/2013
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-013-0843-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version

JSN, JRS, and JCS Joint Working Group

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: a multicenter prospective study in Japan

Overt intracardiac shunt flow after arteriovenous graft placement

Effects of amino acids and albumin on erythropoietin carbamoylation

Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats

Chilaiditi’s sign in a child with nephrotic syndrome

Thyroid hormone replacement therapy for primary hypothyroidism leads to significant improvement of renal function in chronic kidney disease patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin